Last reviewed · How we verify
Xalatan
Xalatan is a Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently FDA-approved for Ocular hypertension, Open-angle glaucoma. Also known as: Preserved latanoprost, prostaglandin analog, latanoprost ophthalmic solution, Topical Prostaglandin, Latanoprost Ophthalmic Solution.
Xalatan, also known as latanoprost, is a medication used to treat increased pressure inside the eye, including ocular hypertension and open-angle glaucoma. It is applied as eye drops and works by activating the prostaglandin F2-alpha receptor, a prostanoid FP receptor agonist.
At a glance
| Generic name | Xalatan |
|---|---|
| Also known as | Preserved latanoprost, prostaglandin analog, latanoprost ophthalmic solution, Topical Prostaglandin, Latanoprost Ophthalmic Solution, BAK-preserved latanoprost |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Target | Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- Foreign body sensation
- Punctate keratitis
- Stinging
- Conjunctival hyperemia
- Blurred vision
- Itching
- Burning
- Increased pigmentation of the iris
- Excessive tearing
- Eyelid discomfort/pain
- Dry eye
- Eye pain
Serious adverse events
- Toxic epidermal necrolysis
- Corneal edema and erosions
- Intraocular inflammation (iritis/uveitis)
- Macular edema, including cystoid macular edema
- Pseudopemphigoid of the ocular conjunctiva
- Asthma and exacerbation of asthma
- Angina
- Unstable angina
- Herpes keratitis
- Keratitis
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Effect of IOP Lowering on Progressive HM (NA)
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xalatan CI brief — competitive landscape report
- Xalatan updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI
Frequently asked questions about Xalatan
What is Xalatan?
What is Xalatan used for?
Who makes Xalatan?
Is Xalatan also known as anything else?
What development phase is Xalatan in?
What are the side effects of Xalatan?
What does Xalatan target?
Related
- Target: All drugs targeting Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor
- Manufacturer: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Ocular hypertension
- Indication: Drugs for Open-angle glaucoma
- Also known as: Preserved latanoprost, prostaglandin analog, latanoprost ophthalmic solution, Topical Prostaglandin, Latanoprost Ophthalmic Solution, BAK-preserved latanoprost
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing